EPIC: Effect of Povidone Iodine Periurethral Cleansing on Level of Contamination With Clean Catch

Sponsor
Travis Callahan (U.S. Fed)
Overall Status
Completed
CT.gov ID
NCT03933436
Collaborator
(none)
20
1
2
5.9
3.4

Study Details

Study Description

Brief Summary

The primary aim of this study is to see if the use of an antiseptic preparation (povidone iodine) versus cold normal saline, will decrease rates of urine contamination during the non-invasive Quick Wee (QW) collection of pediatric urine.

Condition or Disease Intervention/Treatment Phase
  • Other: Iodine swabs.
  • Other: Saline flush.
N/A

Detailed Description

Urinary tract infections (UTI) are common acute illnesses among pediatric patients, accounting for 5-7% of emergency department visits in the under two-year-old population. However, obtaining urine samples from the precontinent patient can be difficult. There is an ongoing debate regarding which noninvasive method for urine specimen collection is best for this population. The main argument against clean catch is the high rate of contamination compared to invasive collection and reliability.

There are many methods of noninvasive urine collection. These methods are preferred as they are fairly well tolerated by patients, less distressing to parents, cost effective, and require less technical expertise. In the past; these methods have been dismissed due to their high rates of contamination, time to void and also effectiveness. The National Institute of Health and Clinical Excellence (NICE, UK) recommends a clean-catch urine (CCU) be the first attempt at obtaining a urine specimen from children suspected of having UTI. This means placing the urine specimen collection container into the urine mid-stream once the child has begun to void to avoid contamination. Conversely, the American Academy of Pediatrics recommends clean catch urine for screening and a catheter specimen urine collection or suprapubic aspiration for definitive diagnosis. Both of these invasive techniques produce quick urine samples with low rates of contamination; however they can be painful and distressing to both the patient and parent.

The Quick-Wee method for noninvasive urine collection has been evaluated in a one randomized controlled trial and has been shown to significantly increase the five minute voiding success rate for CC urine collection; 31%, n= 174. However a past study demonstrated contamination rate of 27%, n=174. No study has directly evaluated the use of antiseptic solution in the evaluation of the QW rate of contamination in pediatric patients. The purpose of this study is to see whether the use of povidone iodine swabs prior to the QW method will decrease the rate of contamination. A decrease of the rate of contamination would strengthen the validity of this simple CCU method. Also using the this method for the collection method in both the experimental and control groups will further evaluated the five min void success rate.

The investigators chose to use iodine as the prepping agent because it is currently the standard cleaning solution used for adult and pediatric patients. It is readily available, inexpensive and has been shown to be less caustic then other prepping agents.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
EPIC: Effect of Povidone Iodine Periurethral Cleansing on Level of Contamination With Clean Catch: A Randomized Control Trial
Actual Study Start Date :
May 1, 2019
Actual Primary Completion Date :
Oct 28, 2019
Actual Study Completion Date :
Oct 28, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Iodine

Iodine swabs.

Other: Iodine swabs.
Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.

Active Comparator: Normal Saline

Saline flush.

Other: Saline flush.
Children will then have their periurethral region gently cleansed for ten seconds with saline flush.

Outcome Measures

Primary Outcome Measures

  1. Number of participant samples indicating urine contamination [24 to 48 hours]

    Binary yes/no outcome of detection of microbial markers to determine level of contamination

Secondary Outcome Measures

  1. Number of participants who void urine [5 minutes]

    Binary yes/no outcome of voiding urine

Eligibility Criteria

Criteria

Ages Eligible for Study:
28 Days to 12 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study

Inclusion Criteria:
  • DoD children aged one month (28 days) to 12 months (365 days) (if the child was born less than 36 weeks gestation, age will be corrected)

  • Precontinent (meaning that the child is unable to void on command)

  • Treating clinician has determined that the child requires urine sample collection for course of treatment.

Exclusion Criteria:
  • If the treating clinician has determined that there is a need for immediate treatment and urine sample collection via invasive method, any type of anatomical or neurologic condition that will affect the ability to void or sensation of the suprapubic area.

  • Children with past hypersensitivity reactions to iodine swabs.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mike O'Callaghan Military Medical Center Las Vegas Nevada United States 89191

Sponsors and Collaborators

  • Travis Callahan

Investigators

  • Study Director: Paul F Crawford, MD, Mike O'Callaghan Military Medical Center, 99MDG, US Air Force

Study Documents (Full-Text)

More Information

Publications

Responsible Party:
Travis Callahan, Principal Investigator, Mike O'Callaghan Military Hospital
ClinicalTrials.gov Identifier:
NCT03933436
Other Study ID Numbers:
  • FWH20190009H
First Posted:
May 1, 2019
Last Update Posted:
May 21, 2020
Last Verified:
May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of May 21, 2020